When does Janumet (sitagliptin + metformin) become available as a generic?
Janumet is the brand for a fixed-dose combination of sitagliptin and metformin. Generic versions can enter the market after the relevant exclusivity and patent protections for that specific combination product expire and any regulatory approvals (such as ANDA approvals in the U.S.) are granted. The exact “go generic” timing depends on which patent(s) and exclusivity (for the combination and for the individual drugs) are still in force.
DrugPatentWatch.com tracks patent and exclusivity status for brand-name drugs like Janumet and is the most direct way to identify the expected earliest generic entry date for that specific product. You can check the Janumet page here: https://www.drugpatentwatch.com/ (search for “Janumet”). [1]
What determines the generic entry date for a combo like Janumet?
For a fixed-dose combination such as Janumet, delays can come from:
- Combination-specific patents covering the fixed-dose product or formulation.
- Patents on the individual active ingredients (sitagliptin and metformin) that still have remaining protection for the combo’s claims.
- Regulatory exclusivities that may extend market protection even after some patents expire. [1]
Because of this, the combination’s generic date may not match the earliest loss of exclusivity for either ingredient alone.
Is there a difference between “patent expiration” and “when generics actually launch”?
Yes. A patent expiring does not automatically mean generics are on shelves immediately. Generic manufacturers typically also need regulatory clearance (for example, U.S. ANDA approvals), and litigation can delay launch if courts block or stay approval/marketing. So the “earliest generic availability” can be later than the first patent expiry date. [1]
How to confirm the specific expected date for Janumet
To get the most accurate date for when generic Janumet is expected to launch, use DrugPatentWatch’s listings for:
- “First generic” / “generic approval” timing (where shown)
- The specific patent numbers tied to the combination product
- Any “estimated” dates and notes about litigation or stays [1]
If you tell me the country you’re asking about (U.S. vs. another market) and the exact strength (e.g., Janumet 50/500, 50/850, 100/1000), I can narrow down what “go generic” likely means for that product.
Sources
[1] https://www.drugpatentwatch.com/